NEUROSTEMCELLREPAIR
"European stem cell consortium for neural cell replacement, reprogramming and functional brain repair"
| Coordinatore | UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 7˙973˙749 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | coordinator | 1˙758˙620.00 |
| 2 |
CARDIFF UNIVERSITY
Organization address
address: Newport Road 30-36 contact info |
UK (CARDIFF) | participant | 485˙000.00 |
| 3 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 485˙000.00 |
| 4 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 485˙000.00 |
| 5 |
UNIVERSITAETSKLINIKUM BONN
Organization address
address: Sigmund-Freud-Strasse 25 contact info |
DE (BONN) | participant | 485˙000.00 |
| 6 |
THE UNIVERSITY OF EDINBURGH
Organization address
address: OLD COLLEGE, SOUTH BRIDGE contact info |
UK (EDINBURGH) | participant | 438˙000.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
IT (TORINO) | participant | 405˙000.00 |
| 8 |
MILTENYI BIOTEC GMBH
Organization address
address: FRIEDRICH EBERT STRASSE 68 contact info |
DE (BERGISCH GLADBACH) | participant | 370˙000.00 |
| 9 |
ROSLIN CELLS LIMITED
Organization address
address: "ROSLIN BIOCENTRE ROSLIN FOUNDATION, ROSLIN" contact info |
UK (EDINBURGH) | participant | 370˙000.00 |
| 10 |
LIFE AND BRAIN GMBH
Organization address
address: SIGMUND FREUD STR 25 contact info |
DE (BONN) | participant | 358˙380.00 |
| 11 |
INTEGRATED SYSTEMS ENGINEERING SRL
Organization address
address: Via Volturno 80 contact info |
IT (BRUGHERIO) | participant | 180˙000.00 |
| 12 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 180˙000.00 |
| 13 |
LAVISION BIOTEC GMBH
Organization address
address: MEISENSTRASSE 65 contact info |
DE (BIELEFELD) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Neurostemcellrepair aims at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders. PD will be taken as the prototypical disease because stem cell therapy is now close to clinical translation. Moreover, we will tackle next generation issues pertaining to stem cells at a basic level and develop new approaches and novel cell sources, validated at pre-clinical stages, for both PD and HD. The project teams represent a wide range of competences, including stem cell specialists, developmental neurobiologists, experts in neurodegeneration, scientists with links to the clinic and stem cell manufacturing/clinical validation. The research plan is constructed on exchange of tools, sharing of protocols and expertise and joint deliverables among the participants. We will address issues related to the control of progenitor proliferation and differentiation into authentic, functional and phenotypically stable dopaminergic or striatal neurons, and exploit new technology for cell reprogramming. We will develop strategies to obtain endurable donor cell engraftment in the host, including acquisition of specific neuronal identities and functional integration in the recipient brain. The therapeutic effect will be evaluated following transplantation in animal models of PD and HD. Cutting edge technologies will be guaranteed by the involvement of three SMEs, one industry and partners experienced in bioengineering, who will collectively provide a toolbox to deliver ontogenetic and reprogramming factors, small molecules and miRNA, immunoseparation strategies, in vivo monitoring of donor cell behaviour, scale up and GMP-compliant protocols. Ultimately, Neurostemcellrepair is expected to develop new cell sources based on cellular reprogramming, make significant advance towards stem cell therapy in HD, and close the gap between development and clinical implementation of stem cell replacement therapies for PD.'